Quote:
Originally Posted by msink28
I guess I find it difficult to believe that Chet's 25-26 season could be so bad that no team in the NBA would offer him a max contract as an RFA next summer. I find it more likely that he makes a leap and becomes more expensive to retain. Regarding the difference between 25% of the cap and 30% of the cap, that's a rotation guy, roughly 8.5 million per year, or almost exactly what they're paying Jaylin Williams.
I think this is a difference in belief, not really an argument.
Regarding the poison pill, I could be mistaken, but I think Brooklyn could probably swing a deal for him today and absorb his hit, not as if OKC has any desire to do this. But sure, yeah, next year I think if he were on the market there would be a line out the door for the opportunity to trade for him unless he gets badly injured again, in which case I think some teams might still kick the tires on him.
|
New CBA allows teams to negotiate with their own players earlier; OKC could max Chet next summer before any other team gets the chance to offer. We need more details on the terms of the extension, specifically all-nba/DPOY provisions. To see how much they ‘saved’. Rotation guys are extremely valuable in the new CBA. OKC wouldn’t have beat Denver with no Hartenstein/Jaylin Williams. There will be no Hartenstein after next season when these deals kick in.
The poison pill is not just cost for acquiring team but return value as well. Poison pill takes the eligible trade pool and shrinks it to practically nothing—basically other rookie max guys whose teams would never willingly trade them.